1. Knudtzon S. In vitro growth of granulocytic colonies from circulating cells in human cord blood. Blood. 1974;43(3):357-61.
  2. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174-1178.
  3. Harris D, Schumacher M, LoCascio J, et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proceedings of the National Academy of Sciences. 1992;89:10006-10010.
  4. Harris D, Schumacher M, LaCascio J, et al. Immunoreactivity of umbilical cord blood and post partum maternal peripheral blood with regard to HLA haploidentical transplantation. Bone Marrow Transplantation. 1994;14:16-38.
  5. Hao Q, Shah AJ, Thiemann FT, et al. A functional comparison of CD34 + CD38- cells in cord blood and bone marrow. Blood. 1995;86:3745-3753.
  6. Linden JV, Preti RA, Dracker R. New York state guidelines for cord blood banking. Journal of Hematotherapy. 1997;6:535-41.
  7. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337(6):373-381.
  8. Fountain D, Ralston M, Higgins N, et al. Liquid nitrogen freezers: a potential source of microbial contamination of hematopoietic stem cell components. Transfusion. 1997;37(6):585-591.
  9. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000;342(25):1846-1854.
  10. Marco F, Bureo E, Ortega JJ, et al. High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Journal of Clinical Oncology.2000;18:3256-3261.
  11. Alonso JM, 3rd, Regan DM, Johnson CE, et al. A simple and reliable procedure for cord blood banking, processing, and freezing: St Louis and Ohio Cord Blood Bank experiences. Cytotherapy. 2001;3(6):429-433.
  12. Lee O.k. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004 103:1669-1675.
  13. Behzad-Behbahani A, Pouransari R, Tabei SZ, et al. Risk of viral transmission via bone marrow progenitor cells versus umbilical cord blood hematopoietic stem cells in bone marrow transplantation. Transplant Proc. 2005;37(7):3211-3212.
  14. McGuckin CP, Forraz N, Baradez MO, et al. Production of stem cells with embryonic characteristics from human umbilical cord blood. Cell Prolif. 2005;38(4):245-55.
  15. Kurtzberg J, Cairo MS, Fraser JK, et al. Results of the Cord Blood Transplantation (COBLT) Study unrelated donor banking program. Transfusion. 2005;45:842-855.
  16. Meier C, et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatric Research. 2006;59:244-249.
  17. Perlow JH. Patient’s knowledge and understanding of umbilical cord blood banking. Journal of Reproductive Medicine. 2006;51(8):642-8.
  18. Arora M, Nagaraj S,Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant, 2007;13:1145’52.
  19. Hayani A, Lampeter E, Viswanatha D, et al. First report of autologous cord blood transplantation in the treatment of a child with leukemia. Pediatrics. 2007;119:296-300.
  20. Papassavas AC, Gioka V, Chatzistamatiou T, et al. A strategy of splitting individual high volume cord blood units into two half subunits prior to processing increases the recovery of cells and facilitates ex vivo expansion of the infused hematopoietic progenitor cells in adults. Int Jnl Lab Hem. 2007;1-9.
  21. Harris DT, Rogers I. Umbilical Cord Blood: The potential of cord blood stem cells for use in regenerative medicine. Expert Opin. Biol. Ther. 2007 Sep;7(9):1311-22.
  22. Brunstein CG, Setubal DC, Wagner JE. Expanding the role of umbilical cord blood transplantation. Br J Haematol. 2007;137(1):20-35.
  23. Harris DT. Umbilical Cord Blood A Unique Source of Pluripotent Stem Cells for Regenerative Medicine. Current Stem Cell Research & Therapy, 2007, 2, 301-309
  24. Nietfeld JJ, Pasquini MC, Logan BR, et al. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.
  25. Harris DT. Collection, Processing, and Banking of Umbilical Cord Blood Stem Cells for Clinical Use in Transplantation and Regenerative Medicine. LABMEDICINE Volume 39 Number 3 March 2008
  26. Scaradavou A, Stevens C, Dobrila L, et al. Cord Blood (CB) Unit Mononuclear Cell (MNC) Dose: Effect on Transplantation Outcome and Relevance to Processing Method and CBU Selection. Blood. 2008;112:1969.
  27. Baumert B, Grymula K, Pietruszka D, et al. An optimization of hematopoietic stem and progenitor cell isolation for scientific and clinical purposes by the application of a new parameter determining the hematopoietic graft efficacy. Folia Histochem Cytobiol. 2008;46(3):299-305.
  28. Rubinstein P. Cord blood banking for clinical transplantation. Bone Marrow Transplantation. 2009;44:635-642
  29. Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regenerative Med. 2010 Jan; 5(1):121-143.
  30. Goines P, Van de Water J. The immune system’s role in the biology of autism. Curr Opinion in Neurol. 2010;23(2):111-117. doi:10.1097/WCO.0b013e3283373514.
  31. Rastegar F, Shenaq D, Huang J, et al. Mesenchymal stem cells: Molecular characteristics and clinical applications. World Journal of Stem Cells. 2010;2(4):67-80. doi:10.4252/wjsc.v2.i4.67.
  32. Sodian R, Schaefermeier P, Abegg-Zips S, et al. Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann Thorac Surg. 2010; 89(3):819-28
  33. Grayson WL. Engineering anatomically shaped human bone grafts. PNAS.2010;107(8):3299–3304
  34. Morettie, P, Hatlapatka, T, Marten, D, et al. Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applications. Adv Biochem Engin/Biotechnology. 2010;123:29-54.
  35. Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Research & Therapy. 2010;12:R210.
  36. Delaney C. Notch Mediated Expansion of human Cord Blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010 February ; 16(2): 232. doi:10.1038/nm.2080.
  37. Scaradavou A. Cord Blood Units with Low CD341 Cell Viability Have a Low Probability of Engraftment after Double Unit Transplantation. Biol Blood Marrow Transplant 16: 500-508 (2010)
  38. Lin YC, Ko TL, Shih YH, et al. Human Umbilical Mesenchymal Stem Cells Promote Recovery After Ischemic Stroke. Stroke. 2011.
  39. Rosenthal J. Hematopoietic Cell Transplantation With Autologous Cord Blood in Patients With Severe Aplastic Anemia: An Opportunity to Revisit the Controversy Regarding Cord Blood Banking for Private Use. Pediatr Blood Cancer 2011;56:1009–1012
  40. Kim AK, Kim MH, Kim S, et al. Stem-cell Therapy for Peripheral Artery Occlusive Disease. European Journal of Vascular Surgery. 2011.
  41. Haller, M.J. et al. Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. 2011 Diabetes Care 34, 2567–2569.
  42. Jung KH, Uhm YK, Lim YJ, et al. Human umbilical cord blood-derived mesenchymal stem cells improve glucose homeostasis in rats with liver cirrhosis. International Journal of Oncology. 2011.
  43. Bizzetto R, Bonfim C, Rocha V, et al. Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica. 2011;96(1):134-41.
  44. Butler MG, Menitove JE. Umbilical cord blood banking: an update. J Assist Reprod Genet.2011;28(8):669-76.
  45. Forraz N, McGuckin CP. The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine. Cell Prolif. 2011;44 Suppl 1:60-9.
  46. Trounson A, Thakar R, Lomax G, Gibbons D. Clinical Trials for Stem Cell Therapies. BMC Medicine. 2011.
  47. Liao Y, Geyer MB, Yang AJ, Cairo MS. Cord blood transplantation and stem cell regenerative potential. Exp Hematol. 2011;39:393–412.
  48. Broxmeyer HE, Lee MR, Hangoc G, et al. Hematopoietic stem/progenitor cells, generation of induced pluripotent stem cells, and isolation of endothelial progenitors from 21- to 23.5-year cryopreserved cord blood. Blood. 2011;117(18):4773-7.
  49. Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011;117(8):2332-9.
  50. Pope B, Mitsakos K, Bilgin A, Hokin B, Grant R. Predicting overall viability of cord blood harvests. Transfusion. 2012 ;52:1079’1085.
  51. Choudhery MS, Brown KS, Harris DT. Differentiation of MSCs Isolated from Cryopreserved Cord Tissue. Transfusion. 2012. 52(S3).SP357
  52. Liao Y et al. Rescuing the neonatal brain from hypoxic injury with autologous cord blood. Bone Marrow Transplant. 2012.
  53. Solves P. Qualitative and quantitative cell recovery in umbilical cord blood processed by two automated devices in routine cord blood banking a comparative study. Blood Transfus 2013; 11: 405-11 DOI 10.2450/2012.0037-12.
  54. Chao Y. Umbilical Cord-Derived Mesenchymal Stem Cells for Hematopoietic Stem Cell Transplantation. Journal of Biomedicine and Biotechnology, Volume 2012, Article ID 759503, 5 pages, doi:10.1155/2012/759503
  55. Craig ME. Research using autologous cord blood — time for a policy change. MJA 199 (4) · 19 August 2013
  56. Allan D. A Review of Factors Influencing the Banking of Collected Umbilical Cord Blood Units. Hindawi Publishing Corporation, Stem Cells International, Volume 2013, Article ID 463031, 7 pages,
  57. “Media Fact Sheet: 1 Million Blood Stem Cell Transplants Worldwide” 2013.
  58. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013;34(6):747-54.
  59. Lv YT, Zhang Y, Liu M, et al. Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. J Translational Med. 2013 Aug 27; 11:196. doi:10.1186/1479-5876-11-196.
  60. Haller, M.J. et al. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. 2013. Biol. Blood Marrow Transplant. 19, 1126–1129.
  61. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013.
  62. Munoz J, Shah N, Rezvani K, et al. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med. 2014;3:1435-1443. *This number includes cord blood stored publicly and privately.
  63. Guidance for Industry Biologics License Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. March 2014.
  64. Ballen KK, Verter F, Kurtzberg J, Umbilical Cord blood donation: public or private? Bone Marrow Transplant. 2015;50:1271-1278
  65. Sun JM, Kurtzberg J. Cord blood for brain injury. Cytotherapy. 2015 June; 17 (6):775-785. doi:10.1016/j.jcyt.2015.03.004.
  66. Delaney C. Notch-mediated expansion of cord blood progenitors: maintenance of transcriptional and epigenetic fidelity. 2015 September; 29(9): 1948–1951. doi:10.1038/leu.2015.61.
  67. Magalon J, Maiers M, Kurtzberg J, Navarrete C, Rubinstein P, Brown C, et al. (2015) Banking or Bankrupting: Strategies for Sustaining the Economic Future of Public Cord Blood Banks. PLoS ONE 10(12): e0143440.
  68. Corsano B. Allogeneic versus Autologous: ethical issues in umbilical cord blood use. JAHR, Vol. 6/1, No. 11, 2015
  69. Duggleby R. Umbilical Cord Blood-Derived Therapies as a Treatment for Graft-Versus-Host Disease. (2016)
  70. Juric MK, (2016) Milestones of Hematopoietic Stem Cell Transplantation – From First Human Studies to Current Developments. Front. Immunol. 7:470.doi: 10.3389/fimmu.2016.00470
  71. Harris DT. Long-term frozen storage of stem cells challenges and solutions. Journal of Biorepository Science for Applied Medicine 2016:4 9–20
  72. Delaney C. Cellular engineering and therapy in combination with cord blood allografting in pediatric recipients. Bone Marrow Transplantation (2016) 51, 27–33; doi:10.1038/bmt.2015.196.
  73. Young W. Phase I–II Clinical Trial Assessing Safety and Efficacy of Umbilical Cord Blood Mononuclear Cell Transplant Therapy of Chronic Complete Spinal Cord Injury. Cell Transplantation, Vol. 25, pp. 1925–1943, 2016
  74. Seay HR et al. Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. 2017. Mol Ther Methods Clin Dev. 2016 Dec 24;4:178-191.
  75. Delaney C. Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transplantation (2016) 51, 1588–1593
  76. Tiwari A. Exploring Life Saving Potential of Umbilical Cord Blood Derived Hematopoietic Stem Cells. Insights in Stem Cells, 2016, vol 2 np 10
  77. Dawson G, Sun JM, et. al. (2017) Autologous cord blood infusions are safe and feasible in young children with autism spectrum disorder: results of a single-center phase 1 open-label trial. Stem Cells Translational Med. 2017 May; 6(5):1332-1339.
  78. Ballen K. Update on umbilical cord blood transplantation. F1000Res. 2017;6:1556. doi: 10.12688/f1000research.11952.1.
  79. Couto PS, Bersenev A, Verter F. The first decade of advanced cell therapy clinical trials using perinatal cells (2005-2015). Regenerative Medicine. 2017;12(8):953-968. doi:10.2217/rme-2017-0066.
  80. Saleh R, Reza HM. Short review on human umbilical cord lining epithelial cells and their potential clinical applications. Stem Cell Res Ther. 2017;8(1):222. Published 2017 Oct 10. doi:10.1186/s13287-017-0679-y
  81. Zhang H, Tao Y, Ren S, et al. Isolation and characterization of human umbilical cord-derived endothelial colony-forming cells. Exp Ther Med. 2017;14(5):4160-4166.
  82. Volarevic, V., Gazdic, M., Simovic Markovic, B., et al. Mesenchymal stem cell-derived factors: Immuno-modulatory effects and therapeutic potential. Biofactors. 2017 Sep 10;43(5):633-644. doi: 10.1002/biof.1374.
  83. Sun JM, Song AW, Case LE, et al. Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children with Cerebral Palsy: A Randomized, Placebo-Controlled Trial. Stem Cells Translational Medicine. 2017;6(12):2071-2078. doi:10.1002/sctm.17-0102.
  84. Anand S. Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization. Biol Blood Marrow Transplant 23 (2017) 1151–1157
  85. Bartolucci J. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial). Circ Res. 2017;121:1192-1204. DOI: 10.1161/CIRCRESAHA.117.310712
  86. Kurtzberg J. A History of Cord Blood Banking and Transplantation. Stem Cells Translational Medicine 2017;6:1309–1311
  87. Kurtzberg J. Announcing a New Journal Section: Cord Blood. Stem Cells Translational Medicine 2017;6:1307–1308
  88. Mazonson P. Prevalence of Medical Conditions Potentially Amenable to Cellular Therapy among Families Privately Storing Umbilical Cord Blood. Matern Child Health J (2017) 21:208–214.
  89. ACOG Committee Opinion. Number 684, January 2017. Delayed Umbilical Cord Clamping after birth.
  90. Horwitz ME. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. J Clin Oncol 37:367-374. © 2018 by American Society of Clinical Oncology
  91. Baumgartner LS, Moore E, Shook D, et al. Safety of Autologous Umbilical Cord Blood Therapy for Acquired Sensorineural Hearing Loss in Children. Journal of Audiology & Otology 2018 doi: 10.7874/jao.2018.00115
  92. Dessels C, Alessandrini M, Pepper M.S. Factors Influencing the Umbilical Cord Blood Stem Cell Industry: An Evolving Treatment Landscape. Stem Cells Transl Med. 2018 Sep;7(9):643-650.
  93. Chez M, Lepage C, Parise C, Dang-Chu A, Hankins A, Carroll M. Safety and observations from a placebo-controlled, crossover study to assess use of autologous umbilical cord blood stem cells to improve symptoms in children with autism. Stem Cells Translational Med. 2018 Feb 6.
  94. Huang L. A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children with Cerebral Palsy. Cell Transplantation 2018, Vol. 27(2) 325–334
  95. Laskowitz DT. Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study. Stem Cells Translational Medicine 2018;7:521–529
  96. Meng M. Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis. Am J Transl Res 2018;10(1):212-223
  97. Riordan NH. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis J Transl Med (2018) 16:57
  98. Verter F. A dozen years of clinical trials performing advanced cell therapy with perinatal cells. Future Sci. OA (2018) 4(10), FSO351
  99. Paschalaki KE, Randi AM. Recent Advances in Endothelial Colony Forming Cells Toward Their Use in Clinical Translation. Front Med (Lausanne). 2018;5:295. Published 2018 Oct 23. doi:10.3389/fmed.2018.00295
  100. Skiles ML, Brown KS, Tatz W, Swingle K, Brown HL. Quantitative analysis of composite umbilical cord tissue health using a standardized explant approach and an assay of metabolic activity. Cytotherapy. 2018.
  101. Qu X, Sheng H. Stem Cell Therapy for Traumatic Brain Injury: A Progress Update. Ann Neurol Surg. 2018; 2(1):1008.
  102. Sutten M et al. Anti-Inflammatory Therapeutic Development and Optimization of Umbilical Cord Tissue Derived Mesenchymal Stem Cells. Journal of Stem Cell Research and Therapy. 2018, 8:8.
  103. Alliance for Regenerative Medicine. 2018 Annual Industry Report.
  104. Arutyunyan I. Umbilical cord tissue cryopreservation: a short review. Stem Cell Research & Therapy (2018) 9:236
  105. Balassa K. Anticancer cellular immunotherapies derived from umbilical cord blood. Expert Opin Biol Ther. 2018 Feb;18(2):121-134. doi: 10.1080/14712598.2018.1402002.
  106. Peberdy L. Parents’ knowledge, awareness and attitudes of cord blood donation and banking options An integrative review. BMC Pregnancy and Childbirth (2018) 18:395
  107. Boruczkowski D. Autologous Cord Blood in Children with Cerebral Palsy: A Review. Int. J. Mol. Sci. 2019, 20, 2433; doi:10.3390/ijms20102433
  108. Gupta V. Cord Blood Banking: Antenatal Care Provider’s Roles and Responsibilities. Stem Cells International, Volume 2019, Article ID 3598404, 7 pages,
  109. Feriero DM. Management of Stroke in Neonates and Children A Scientific Statement From the American Heart Association American Stroke Association. Stroke. 2019;50:e51–e96.
  110. Verter F. Public Banking Without Bankrupting. Accessed 13/07/2019
  111. Riordan N.H. Allogeneic Human Umbilical Cord MSCs for the Treatment of Autism Spectrum Disorder in Children Safety Profile and Effect on Cytokine Levels. Stem Cells Translational Medicine 2019;00:1–9.
  112. Harris DT. Harris Stem Cell Banking for Regenerative and Personalized Medicine. Biomedicines 2014, 2, 50-79; doi:10.3390/biomedicines2010050
  113. Accessed 20190709
  114. Accessed 20190717
  115. CDC, Autism Data Visualization Tool: Accessed 20190717.
  116. CDC, 11 Things to Know about Cerebral Palsy: Accessed 20190717
  117. Cord Blood Association. Indications for Utilization of Stored Umbilical Cord Blood. Accessed 20190717
  118. Cord Blood Association. About Cord Blood. Accessed 20190717

Clinical Trial Searches

  1. 20190717 HLHS UCB Trials Search Results
  2. 20190717 ASD UCB Trials Search Results
  3. 20190717 CP UCB Trial Search Results
  4. 20190717 Acquired Hearing Loss UCB Search Results
  5. 20190717 ASD MSCs Search Results
  6. 20190717 UCB Treatment Clinical Trials Search Results
  7. 20190717 UC-MSC Treatment Clinical Trials Search Results

Are you pregnant?

Sign up for educational information about cord blood banking

The treating doctor will determine the use of cord blood for treatment, depending on many factors, including the patient’s medical condition, the quality of the cord blood sample, if the patient’s own cord blood can be used or an adequately matched donor’s cord blood.The use of cord blood has been established in stem cell transplantation and has been used to treat more than 80 diseases. The use of cord blood in regenerative medicine is still being researched and there is no guarantee that treatments being studied in the laboratory, clinical trials, or other experimental treatments will be available in the future.The use of cord tissue stem cells is still in early research stages, and there is no guarantee that treatments using cord tissue stem cells will be available in the future. Cord tissue stem cells are found in the cord tissue which is stored whole. Additional processing will be required to isolate the stem cells from the tissue for use. CELVI (Pty) Ltd outsources all cord blood and tissue processing and storage activities to Next Biosciences in Midrand, South Africa, a licensed and AABB accredited facility.

Notice: Click here to go to the South African COVID-19 Portal